• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.通过流式细胞术检测外周血与骨髓中急性髓系白血病的可测量残留病
Blood. 2021 Jan 28;137(4):569-572. doi: 10.1182/blood.2020006219.
2
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.流式细胞术检测微小残留病对急性髓系白血病患者异基因造血干细胞移植前后的预后影响
Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.
3
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.基于数字液滴 PCR 的移植前 NPM1 突变负担绝对定量可预测急性髓系白血病患者的复发。
Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.
4
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.用于检测急性髓系白血病中可测量残留病和白血病干细胞的骨髓采样与处理综合方案。
J Vis Exp. 2018 Mar 5(133):56386. doi: 10.3791/56386.
5
Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.流式细胞术检测急性白血病中非典型抗原表达以研究微小残留病
Cytometry. 1992;13(8):893-901. doi: 10.1002/cyto.990130813.
6
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.用于急性髓系白血病诊断和监测的骨髓评估
Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2.
7
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.急性髓系白血病的临床反应与微小残留病的关系及其对预后的影响。
J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.
8
Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.流式细胞术对急性髓系白血病的缓解评估在再生障碍时取代了细胞形态学，修正了无分子残留病标志物的病例，并在再生障碍时和诱导后作为独立的预后标志物。
Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4.
9
Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.外周血分子可测量残留病足以识别有临床复发风险的急性髓系白血病患者。
Br J Haematol. 2021 Nov;195(3):310-327. doi: 10.1111/bjh.17449. Epub 2021 Apr 13.
10
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.唐氏综合征特异性非恶性造血再生对骨髓中白血病可测量残留病检测的影响。
Cytometry B Clin Cytom. 2023 Jul;104(4):311-318. doi: 10.1002/cyto.b.22118. Epub 2023 Apr 4.

引用本文的文献

1
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid Leukemia.流式细胞术检测可测量残留病：385例急性髓系白血病连续病例的检测验证与特征分析
Cancers (Basel). 2025 Mar 29;17(7):1155. doi: 10.3390/cancers17071155.
2
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.可测量残留病在接受异基因造血细胞移植治疗急性髓系白血病患者中的意义
Cells. 2025 Feb 15;14(4):290. doi: 10.3390/cells14040290.
3
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.突破骨髓屏障：外周血作为急性髓系白血病可测量残留病检测的途径
Am J Hematol. 2025 Apr;100(4):638-651. doi: 10.1002/ajh.27586. Epub 2025 Jan 7.
4
High-Sensitivity Flow Cytometry for the Reliable Detection of Measurable Residual Disease in Hematological Malignancies in Clinical Laboratories.用于临床实验室中血液系统恶性肿瘤可测量残留病可靠检测的高灵敏度流式细胞术。
Diseases. 2024 Dec 22;12(12):338. doi: 10.3390/diseases12120338.
5
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.使用质谱流式细胞术进行的T细胞免疫聚类分析可识别急性髓系白血病患者的独特亚组。
Blood Adv. 2025 Jan 28;9(2):239-243. doi: 10.1182/bloodadvances.2024014553.
6
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug development.急性髓系白血病中可测量残留病监测：治疗决策与新药研发的前景
Am J Hematol. 2025 Mar;100 Suppl 2(Suppl 2):5-15. doi: 10.1002/ajh.27482. Epub 2024 Sep 25.
7
Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.急性髓系白血病中可测量残留病的检测方法及预后意义
Ann Hematol. 2024 Dec;103(12):4869-4881. doi: 10.1007/s00277-024-06008-z. Epub 2024 Sep 16.
8
When acute promyelocytic leukaemia changes its face in the peripheral blood.当急性早幼粒细胞白血病在外周血中改变其面貌时。
EJHaem. 2024 May 24;5(3):635-637. doi: 10.1002/jha2.887. eCollection 2024 Jun.
9
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.急性髓系白血病中可测量残留病的检测：当前挑战与未来方向
Biomedicines. 2024 Mar 7;12(3):599. doi: 10.3390/biomedicines12030599.
10
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.血液稀释对急性髓系白血病流式细胞术检测残留病的影响。
Leukemia. 2024 Mar;38(3):630-639. doi: 10.1038/s41375-024-02158-1. Epub 2024 Jan 25.

本文引用的文献

1
Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.急性髓系白血病微小残留病灶检测：与常规方法的差异。
Curr Protoc Cytom. 2020 Jun;93(1):e73. doi: 10.1002/cpcy.73.
2
Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.急性髓细胞白血病中通过流式细胞术评估外周血微小/可测量残留病
Leukemia. 2019 Jul;33(7):1814-1816. doi: 10.1038/s41375-019-0393-0. Epub 2019 Feb 5.
3
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.急性髓系白血病中的微小残留病：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.
4
Estimation of rank correlation for clustered data.聚类数据的秩相关估计。
Stat Med. 2017 Jun 30;36(14):2163-2186. doi: 10.1002/sim.7257. Epub 2017 Apr 11.
5
Measurable residual disease testing in acute myeloid leukaemia.急性髓系白血病的可测量残留病检测。
Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7.
6
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
7
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?异基因造血细胞移植治疗急性髓系白血病：是时候转向基于微小残留病的完全缓解定义了吗？
J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.
8
Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.外周血微小残留病可能取代骨髓微小残留病成为急性髓系白血病复发的免疫表型生物标志物。
Leukemia. 2016 Mar;30(3):708-15. doi: 10.1038/leu.2015.255. Epub 2015 Sep 16.
9
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.在首次和第二次完全缓解的 AML 患者中，在清髓性异基因造血细胞移植前进行微小残留病检测的意义。
Blood. 2013 Sep 5;122(10):1813-21. doi: 10.1182/blood-2013-06-506725. Epub 2013 Jul 11.
10
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.多参数流式细胞术检测移植前微小残留病对急性髓系白血病清髓性造血细胞移植结局的影响。
J Clin Oncol. 2011 Mar 20;29(9):1190-7. doi: 10.1200/JCO.2010.31.8121. Epub 2011 Jan 31.

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.

作者信息

Godwin Colin D, Zhou Yi, Othus Megan, Asmuth Mallette M, Shaw Carole M, Gardner Kelda M, Wood Brent L, Walter Roland B, Estey Elihu H

机构信息

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Department of Medicine, Division of Hematology, and.

出版信息

Blood. 2021 Jan 28;137(4):569-572. doi: 10.1182/blood.2020006219.

DOI:10.1182/blood.2020006219
PMID:33507294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7845008/
Abstract
摘要